GeneralNeutralCrypto Briefing · 5h ago6/10
📰
GSK acquires Nuvalent for $10.6 billion to rebuild its oncology business
GSK announced a $10.6 billion acquisition of Nuvalent to strengthen its oncology pipeline and rebuild its cancer drug portfolio. The deal represents a significant strategic shift for the pharmaceutical giant, leveraging Nuvalent's innovative targeted therapy platform to enhance its competitive position in the high-value oncology market.
